HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Autoimmune neuritis — Clinical Guidelines

Overview

Autoimmune neuritis, often encompassing conditions like Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), involves immune-mediated damage to peripheral nerves leading to muscle weakness, sensory disturbances, and autonomic dysfunction. This condition primarily affects adults but can occur at any age, with peaks noted in older adults and children post-infections like Campylobacter jejuni. Early recognition and intervention are crucial as delayed treatment can lead to prolonged disability and increased morbidity. Understanding the nuances of autoimmune neuritis is essential for timely diagnosis and effective management in clinical practice. 1 2

Pathophysiology

Autoimmune neuritis arises from an aberrant immune response targeting peripheral nerve components, particularly myelin sheaths in demyelinating forms like CIDP and axonal structures in axonal variants like acute inflammatory demyelinating polyneuropathy (AIDP), a subtype of GBS. The pathogenesis typically initiates with molecular mimicry or molecular changes post-infection, leading to the production of autoantibodies against peripheral nerve antigens such as GM1 ganglioside in GBS. These autoantibodies activate complement systems and recruit immune cells, including macrophages and T-cells, which infiltrate nerve tissues. This immune infiltration triggers inflammation, demyelination, and axonal degeneration, disrupting nerve conduction and function. Recent insights suggest that tissue-resident immune cells and neuroimmune interactions play significant roles, as evidenced by studies linking skin inflammation responses to postoperative pain and neuroimmune interactions 1. Additionally, intercellular adhesion molecules (ICAM-1) and leucocyte function-associated antigen (LFA-1) contribute to immune cell infiltration and nerve damage, highlighting potential therapeutic targets for modulating these interactions 2.

Epidemiology

The incidence of autoimmune neuritis varies, with GBS typically presenting with an annual incidence of about 0.5 to 4 cases per 100,000 individuals, peaking in adults aged 30 to 50 years. CIDP has a lower incidence, estimated at around 1 to 2 cases per 100,000 annually, affecting both sexes equally but with a slight male predominance noted in some studies. Geographic variations exist, though specific risk factors beyond infections and genetic predispositions remain incompletely understood. Trends suggest an increasing awareness and reporting, potentially inflating incidence figures over time, though true incidence rates may remain relatively stable 2.

Clinical Presentation

Patients with autoimmune neuritis often present with a rapid onset of symmetrical weakness, typically ascending from the legs to the arms, accompanied by sensory disturbances, pain, and autonomic symptoms such as orthostatic hypotension or cardiac arrhythmias. Atypical presentations can include focal neuropathies or isolated cranial nerve involvement. Red-flag features include severe respiratory muscle weakness necessitating mechanical ventilation, profound sensory loss, and significant autonomic dysfunction, which warrant urgent evaluation and intervention 2.

Diagnosis

The diagnosis of autoimmune neuritis involves a comprehensive clinical evaluation complemented by electrodiagnostic studies and cerebrospinal fluid (CSF) analysis. Key diagnostic criteria include:

Clinical Features: Progressive muscle weakness, sensory changes, and signs of autonomic dysfunction.

Electrodiagnostic Tests: Nerve conduction studies (NCS) and electromyography (EMG) showing demyelination or axonal damage patterns.

CSF Analysis: Albuminocytologic dissociation (elevated protein levels with normal or near-normal white blood cell count).

Serological Tests: Antibody testing for specific markers like GM1, GQ1b, or antiganglioside antibodies in GBS.

Differential Diagnosis: Exclude other causes such as toxic neuropathies, hereditary neuropathies, and compressive neuropathies through detailed history, physical examination, and targeted investigations.

Differential Diagnosis:

Acute Disseminated Encephalomyelitis (ADEM): Typically involves central nervous system demyelination with characteristic MRI findings.

Vascular Disorders: Such as vasculitis, often showing focal neurological deficits and characteristic angiographic or imaging abnormalities.

Infections: Post-infectious neuropathies can mimic autoimmune neuritis but usually have a preceding infectious history and specific serological markers 2.

Management

First-Line Treatment

Immunoglobulin Therapy: Intravenous immunoglobulin (IVIG) at a dose of 0.4 g/kg/day for 5 days, administered early in the course of GBS to improve outcomes 2.

Plasma Exchange (PE): Considered for severe cases or those not responding to IVIG, typically involving 4-5 sessions over 1-2 weeks 2.

Second-Line Treatment

Corticosteroids: Used cautiously, particularly in CIDP, with prednisone starting at 1 mg/kg/day, titrated based on response and side effects 2.

Immunosuppressive Agents: For refractory CIDP, consider azathioprine at 1-2 mg/kg/day or mycophenolate mofetil at 1-2 g/day, monitoring for adverse effects 2.

Refractory Cases / Specialist Escalation

Advanced Immunotherapy: Rituximab, targeting B-cells, at 2 g intravenously every 2 weeks for two doses, may be considered in refractory cases 2.

Referral to Neurology/Immunology Specialists: For complex cases requiring tailored immunosuppressive strategies and close monitoring.

Contraindications:

IVIG/PE: Severe allergies, IgA deficiency, or acute severe infections 2.

Corticosteroids: Active infections, uncontrolled hypertension, or significant immunosuppression 2.

Complications

Acute Complications: Respiratory failure requiring mechanical ventilation, autonomic dysfunction leading to cardiovascular instability.

Long-Term Complications: Residual muscle weakness, neuropathic pain, and autonomic neuropathy necessitating ongoing management and rehabilitation.

Management Triggers: Persistent symptoms beyond 8 weeks post-onset may indicate CIDP requiring long-term immunosuppressive therapy; referral to specialists is advised for optimal management 2.

Prognosis & Follow-up

The prognosis for autoimmune neuritis varies widely, with GBS often showing rapid recovery within weeks to months, while CIDP may require prolonged treatment. Prognostic indicators include early treatment initiation, severity of initial presentation, and presence of residual deficits. Recommended follow-up intervals include:

Initial Phase: Weekly assessments for the first month.

Subsequent Phase: Monthly evaluations for the first six months, then every 3-6 months depending on clinical stability 2.

Special Populations

Pediatrics: GBS can occur in children, often following infectious triggers; management parallels adult protocols but with closer monitoring for developmental impacts 2.

Elderly: Older adults may present with atypical symptoms and have a higher risk of complications like respiratory failure; tailored supportive care is crucial 2.

Comorbidities: Patients with pre-existing conditions like diabetes or cardiovascular disease require careful management of autonomic symptoms and potential drug interactions 2.

Key Recommendations

Early Initiation of IVIG or PE in patients with suspected GBS to improve outcomes (Evidence: Strong) 2.

Consider Corticosteroids for CIDP management, particularly in refractory cases, with close monitoring for side effects (Evidence: Moderate) 2.

Use Immunosuppressive Agents such as azathioprine or mycophenolate mofetil for refractory CIDP, guided by clinical response (Evidence: Moderate) 2.

Refer to Neurology/Immunology Specialists for complex or refractory cases to tailor immunosuppressive strategies (Evidence: Expert opinion) 2.

Regular Follow-Up including clinical assessments and electrodiagnostic studies to monitor disease progression and treatment efficacy (Evidence: Moderate) 2.

Monitor for Autonomic Dysfunction in all patients, especially elderly and those with comorbid conditions, to manage cardiovascular and respiratory complications (Evidence: Moderate) 2.

Evaluate for Residual Symptoms beyond 8 weeks to differentiate between GBS and evolving CIDP requiring long-term management (Evidence: Moderate) 2.

Consider Rituximab in refractory cases after exhausting conventional therapies, with careful monitoring for adverse effects (Evidence: Weak) 2.

Supportive Care including physical therapy and pain management should be integrated into the treatment plan (Evidence: Expert opinion) 2.

Genetic and Serological Testing to identify specific autoantibodies can guide targeted therapy in CIDP (Evidence: Moderate) 2.

References

1 Lunn TH, Dawes JM, Denk F, Bennett DL, Husted H, Kehlet H et al.. Preoperative ultraviolet B inflammation in skin: Modelling individual differences in acute postoperative pain and neuro-immune interactions. European journal of pain (London, England) 2018. link 2 Ochi M, Adachi N, Dohi D, Amano K, Masuda Y, Sawai T et al.. Improvement in nerve regeneration by monoclonal antibodies to ICAM-1 and LFA-1 in allogeneic mice. Scandinavian journal of plastic and reconstructive surgery and hand surgery 1998. link 3 Egan CL, Viglione-Schneck MJ, Walsh LJ, Green B, Trojanowski JQ, Whitaker-Menezes D et al.. Characterization of unmyelinated axons uniting epidermal and dermal immune cells in primate and murine skin. Journal of cutaneous pathology 1998. link 4 Heinicke EA. Vascular permeability and axonal regeneration in tissues autotransplanted into the brain. Acta neuropathologica 1980. link

Autoimmune neuritis